IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE

Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience

HIV Infections*/genetics ; HIV-1*/genetics ; Sexual and Gender Minorities*; Genotype ; Homosexuality, Male ; Humans ; Interferons ; Interleukins/genetics ; Male ; Seroconversion

Individuals lacking interferon lambda 4 (IFNL4) protein due to a common null mutation (rs368234815) in the IFNL4 gene display higher resistance against several infections. The influence of IFNL4 on HIV-1 infection is still under discussion and conflicting results have been reported. This study intended to corroborate or refute the association of the null allele of IFNL4 and HIV-1 predisposition in a cohort of men who have sex with men (MSM). IFNL4 null genotype was assessed on 619 HIV-1-seronegative MSM who were followed for 36 months during a trial of a prophylactic vaccine against HIV-1. Of those, 257 individuals seroconverted during this period. A logistic regression model was constructed including demographic and IFNL4 genotype. In addition, a meta-analysis using data from the current study and other European populations was conducted. The null IFNL4 genotypes were correlated with lower HIV-1 seroconversion (Adjusted OR = 0.4 [95%CI: 0.2-0.8], P = 0.008) and longer time to seroconversion (889 vs. 938 days, P= 0.01). These results were validated by a meta-analysis incorporating data from other European populations and the result yielded a significant association of the IFNL4 null genotype under a dominant model with a lower probability of HIV-1 infection (OR=0.4 [95% CI: 0.3-0.6]; P= 1.3 x 10E-5).

J Infect Dis. 2010 Dec 1;202(11):1749-53. (PMID: 20977343)
Hum Immunol. 2018 Jan;79(1):70-75. (PMID: 29080719)
AIDS Res Hum Retroviruses. 2021 Mar;37(3):184-188. (PMID: 33066718)
Ann Hum Genet. 1984 Jul;48(3):283-6. (PMID: 6465845)
J Gen Virol. 2016 Sep;97(9):2210-2220. (PMID: 27302182)
J Infect Dis. 2011 Jun 1;203(11):1629-36. (PMID: 21592993)
AIDS. 2014 Aug 24;28(13):1885-9. (PMID: 25259701)
J Immunol. 2017 Dec 1;199(11):3808-3820. (PMID: 29070670)
J Med Virol. 2018 Nov;90(11):1779-1783. (PMID: 29992584)
J Interferon Cytokine Res. 2019 Oct;39(10):599-608. (PMID: 31070498)
AIDS. 2020 Jan 1;34(1):25-32. (PMID: 31634193)
Chest. 2017 Apr;151(4):917-929. (PMID: 28007622)
AIDS Res Ther. 2020 Apr 15;17(1):13. (PMID: 32295609)
Nat Genet. 2009 Oct;41(10):1100-4. (PMID: 19749758)
Curr Opin Immunol. 2015 Feb;32:7-12. (PMID: 25463593)
Sci Rep. 2021 Oct 27;11(1):21185. (PMID: 34707167)
J Infect Dis. 2005 Mar 1;191(5):654-65. (PMID: 15688278)
Nat Genet. 2013 Feb;45(2):164-71. (PMID: 23291588)
Clin Microbiol Infect. 2015 Mar;21(3):289.e1-4. (PMID: 25658540)
Clin Infect Dis. 2016 Dec 16;64(5):621-628. (PMID: 27986689)
Am J Hum Genet. 2007 Sep;81(3):559-75. (PMID: 17701901)
J Infect Dis. 2019 Feb 15;219(5):772-776. (PMID: 30289470)
Clin Infect Dis. 2017 Oct 1;65(7):1243-1244. (PMID: 28541547)
PLoS One. 2014 Mar 17;9(3):e91822. (PMID: 24637774)
BMC Bioinformatics. 2017 Dec 16;18(1):563. (PMID: 29246109)
Nat Genet. 2009 Oct;41(10):1105-9. (PMID: 19749757)
AIDS. 2015 Sep 10;29(14):1895-7. (PMID: 26372394)

Keywords: HESN; HIV exposed seronegative; HIV-1; IFNL4; IL28B

0 (IFNL4 protein, human)
0 (Interleukins)
9008-11-1 (Interferons)

Date Created: 20220428 Date Completed: 20220429 Latest Revision: 20220716

20240104

PMC9067526

10.1080/21505594.2022.2066612

35481423